STOCK TITAN
  1. Home
  2. Sec-filings
  3. KROS
  4. [8-K] Keros Therapeutics, Inc. Reports Material Event

Keros Therapeutics (Nasdaq: KROS) CEO to join Goldman Sachs healthcare fireside chat

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Keros Therapeutics, Inc. announced that President and Chief Executive Officer Jasbir S. Seehra, Ph.D., will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on June 8, 2026 at 4:00 p.m. Eastern time.

A live audio webcast and an archived replay for up to 90 days will be available through links on the Investors section of the Keros website. The company is described as a clinical-stage biopharmaceutical business focused on therapeutics targeting dysfunctional signaling of the transforming growth factor-beta family of proteins, with lead candidates rinvatercept and elritercept in development for serious neuromuscular and hematologic disorders.

Positive

  • None.

Negative

  • None.
Item 7.01 Regulation FD Disclosure Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Conference date and time June 8, 2026, 4:00 p.m. Eastern time Goldman Sachs 47th Annual Global Healthcare Conference fireside chat
Webcast replay duration up to 90 days Archived replay available in Investors section of Keros website
Conference edition 47th Annual Goldman Sachs Annual Global Healthcare Conference
Rinvatercept indications Duchenne muscular dystrophy and amyotrophic lateral sclerosis Described as Keros’ lead product candidate
Elritercept indications Cytopenias in myelodysplastic syndrome and myelofibrosis Described as Keros’ most advanced product candidate
Regulation FD regulatory
"Item 7.01 Regulation FD Disclosure."
Regulation FD is a rule that prevents company insiders, like executives, from sharing important information with some people before others get it. It matters because it helps ensure all investors have equal access to key news, making the stock market fairer and reducing chances of insider trading.
clinical-stage biopharmaceutical company financial
"Keros, a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics"
A clinical-stage biopharmaceutical company develops drugs or medical therapies that are being tested in people in formal clinical trials but do not yet have any approved, marketed products. For investors, these firms behave like prototype makers: their value depends heavily on trial results and regulatory decisions, so they can swing widely on a single study, consume cash while testing, and offer either large upside if trials succeed or big downside if they fail.
transforming growth factor-beta medical
"disorders that are linked to dysfunctional signaling of the transforming growth factor-beta"
Transforming growth factor-beta (TGF-β) is a naturally occurring signaling protein that helps control cell growth, inflammation and tissue repair, acting like a traffic cop that tells cells when to divide, change form or calm down. It matters to investors because drugs that block or boost TGF-β can treat cancers, fibrotic diseases and immune disorders, affecting clinical trial outcomes, regulatory risk and the commercial potential of biopharma assets.
Duchenne muscular dystrophy medical
"rinvatercept, is being developed for the treatment of Duchenne muscular dystrophy"
A rare, inherited condition that progressively weakens muscles, Duchenne muscular dystrophy causes the body’s muscle fibers to break down over time, often leading to severe disability. For investors, it matters because the small, well-defined patient population, high unmet medical need and complex regulatory and pricing dynamics mean successes or failures in clinical trials, approvals, or therapies can have outsized effects on a company’s valuation and future revenue prospects.
myelodysplastic syndrome medical
"elritercept, is being developed for the treatment of cytopenias ... in patients with myelodysplastic syndrome"
A bone marrow disorder in which the body’s blood-cell “factory” produces too few or abnormal blood cells, leading to anemia, infections, or bleeding and sometimes progressing to acute leukemia. Investors care because the condition creates clinical and commercial opportunities — drugs, tests and treatments that improve blood counts or delay progression can drive regulatory approvals, patient demand and reimbursement decisions, affecting the value of healthcare and biotech companies.
myelofibrosis medical
"elritercept, is being developed for the treatment of cytopenias ... in patients with myelofibrosis."
A bone marrow disorder in which healthy, spongy marrow is gradually replaced by scar tissue, like a garden soil turned to concrete so seeds can’t grow. That replacement reduces production of red and white blood cells and platelets, causing anemia, fatigue, infections and an enlarged spleen. Investors care because the condition creates demand for therapies, clinical trials and regulatory decisions that can materially affect drug sales and company valuations.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Understanding 8-K Material Events →
0001664710FALSE00016647102026-06-012026-06-01

 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
FORM 8-K 
 
 
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 1, 2026
 
 
Keros Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
 
 
 
Delaware 001-39264 81-1173868
(state or other jurisdiction
of incorporation)
 
(Commission
File Number)
 
(I.R.S. Employer
Identification No.)
1050 Waltham Street, Suite 302
Lexington, Massachusetts
 02421
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code: (617) 314-6297
 
Not applicable
(Former name or former address, if changed since last report.)
 
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) 
 
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) 


 
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) 
Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class 
Trading
Symbol
 
Name of each exchange
on which registered
Common Stock, $0.0001 par value per share KROS The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
 
 


Item 7.01    Regulation FD Disclosure.

On June 1, 2026, Keros Therapeutics, Inc. (the “Company”) issued a press release announcing that Jasbir Seehra, the Company’s President and Chief Executive Officer, will participate in a fireside chat presentation at the Goldman Sachs 47th Annual Global Healthcare Conference on Monday, June 8, 2026 at 4:00 p.m. Eastern time. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.

The information in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section. The information contained herein and in the accompanying exhibit is not incorporated by reference in any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in such filing.

Item 9.01     Financial Statements and Exhibits.
 
(d) Exhibits
Exhibit  
No. Description
99.1
 
Press Release dated June 1, 2026.
104Cover Page Interactive Data File (the cover page XBRL tags are embedded within the Inline XBRL document)


SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
KEROS THERAPEUTICS, INC.
By: /s/ Jasbir Seehra
 
Jasbir Seehra, Ph.D.
Chief Executive Officer
Dated: June 1, 2026


Exhibit 99.1
Keros Therapeutics Announces Participation at Goldman Sachs 47th Annual Global Healthcare Conference

LEXINGTON, Mass., June 1, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that Keros’ President and Chief Executive Officer Jasbir S. Seehra, Ph.D., will participate in a fireside chat presentation at the Goldman Sachs 47th Annual Global Healthcare Conference on Monday, June 8, 2026 at 4:00 p.m. Eastern time.

A live audio webcast of the fireside chat presentation will be available at https://cc.webcasts.com/gold006/060826a_js/?entity=146_YVQJ8LJ and an archived replay will be accessible in the Investors section of the Keros website at https://ir.kerostx.com for up to 90 days following the conclusion of the event.

About Keros Therapeutics, Inc.

Keros is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the TGF-ß family of proteins. Keros is a leader in understanding the role of the TGF-ß family of proteins, which are master regulators of the growth, repair and maintenance of a number of tissues, including skeletal muscle, bone, adipose, heart tissue and blood. By leveraging this understanding, Keros has discovered and is developing protein therapeutics that have the potential to provide meaningful and potentially disease-modifying benefit to patients. Keros’ lead product candidate, rinvatercept, is being developed for the treatment of Duchenne muscular dystrophy and for the treatment of amyotrophic lateral sclerosis. Keros’ most advanced product candidate, elritercept, is being developed for the treatment of cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndrome and in patients with myelofibrosis.

Investor Contact:
Justin Frantz
jfrantz@kerostx.com
617-221-6042


Source: View Original Filing on SEC EDGAR

FAQ

What event is Keros Therapeutics (KROS) highlighting in this 8-K filing?

Keros Therapeutics is highlighting its participation in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on June 8, 2026. CEO Jasbir S. Seehra, Ph.D., will represent the company in this investor-focused discussion.

When will Keros Therapeutics (KROS) present at the Goldman Sachs healthcare conference?

Keros Therapeutics will participate in a fireside chat on Monday, June 8, 2026 at 4:00 p.m. Eastern time. This appearance is part of the Goldman Sachs 47th Annual Global Healthcare Conference, a major industry and investor event.

How can investors access the Keros Therapeutics (KROS) conference webcast?

Investors can access a live audio webcast of the fireside chat via the provided webcast link, with an archived replay available in the Investors section of the Keros website. The replay will remain accessible for up to 90 days after the event.

What type of company is Keros Therapeutics (KROS) according to the filing?

Keros Therapeutics is described as a clinical-stage biopharmaceutical company focused on novel therapeutics targeting dysfunctional signaling of the transforming growth factor-beta family of proteins. These proteins regulate growth, repair and maintenance of tissues like skeletal muscle, bone, heart and blood.

What is Keros Therapeutics’ (KROS) lead product candidate and its intended uses?

Keros’ lead product candidate is rinvatercept. It is being developed for the treatment of Duchenne muscular dystrophy and for amyotrophic lateral sclerosis, two serious neuromuscular diseases with significant unmet medical need, according to the company description.

Which conditions is Keros Therapeutics’ (KROS) candidate elritercept targeting?

Elritercept is described as Keros’ most advanced product candidate. It is being developed to treat cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndrome and in patients with myelofibrosis, both serious bone marrow-related disorders.

Filing Exhibits & Attachments

4 documents

Press Releases

Other Documents